SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is seeing intense retail and institutional focus driven by its massive IPO, index inclusion mandates that force passive funds to buy despite valuation concerns, and bold claims regarding future trillion-dollar revenue potential. The community remains deeply divided, with bulls betting on SpaceX's dominant role in the future space economy, while skeptics view the current valuation as an extreme bubble fueled by hype and lack of fundamental profitability.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as traders weigh record AI infrastructure investment against potential geopolitical shifts and institutional profit-taking. While the community is debating whether recent pullbacks represent a structural reversal or a buying opportunity, active discussions center on the sector's sensitivity to macroeconomic catalysts and the massive liquidity rotation surrounding upcoming high-profile market debuts.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is experiencing intense volatility as market participants react to conflicting signals regarding a potential ceasefire deal in the Middle East and shifting geopolitical dynamics. Investors are actively debating whether the current price action reflects a sustainable recovery or a precarious bull trap, with widespread focus on the divergence between sentiment in the tech sector and broader market indices.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh a wave of overwhelmingly positive R2 test-drive reviews against broader market anxiety and skepticism regarding the company's production execution. While the community remains deeply divided between long-term bulls highlighting the R2 as a definitive Tesla competitor and vocal bears focused on cash burn and thin trading volumes, the primary catalyst remains the highly anticipated commercial rollout of the new SUV platform.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense debate among retail investors, with sentiment split between bearish frustration over its lackluster price action and bullish accumulation driven by its dominant global market position and advertising growth. The stock remains a focal point for the community due to ongoing institutional buying interest that contrasts sharply with the vocal skepticism of retail traders who are questioning the stock's recent performance compared to broader market trends.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as the community highlights the publication of robust Phase 3 trial data in The Lancet Oncology, fueling discussions around its potential as a practice-changing prostate cancer treatment. Investors are closely monitoring upcoming milestones, including the start of a Phase 3 trial for NSCLC and the anticipation of a strategic buyout or partnership, while many actively accumulate shares on pullbacks to position for expected future value.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide Inc. is currently trending as investors react to strong quarterly earnings, featuring significant revenue growth and expanding global fleet operations across 12 countries. The community is actively debating the company's valuation gap compared to Western peers, while closely monitoring news regarding recent partnerships with major OEMs and progress on international robotaxi deployments.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the stock surges following news of a collaboration with NVIDIA to integrate GaN-based power architecture into the MGX ecosystem for AI data centers. Community members are actively debating the company's valuation, institutional positioning, and the long-term impact of potential dilution as they watch for further revenue-generating design wins.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Fremont, CA.

Seagate Technology Holdings Plc

Seagate Technology is trending due to robust demand for high-capacity storage fueled by the AI data center buildout, leading to earnings beats and upward guidance that have attracted intense institutional interest. The community remains highly active in debating the sustainability of this supercycle versus potential valuation bubbles, with ongoing discussions centered on supply bottlenecks, aggressive price target hikes, and comparison to other memory sector leaders.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to positive Phase 1 clinical data for subcutaneous Briumvi, which suggests potential for at-home administration and expansion into myasthenia gravis treatment. Investors are actively discussing the stock's buyout potential and market share growth, while closely monitoring upcoming institutional fireside chats for further catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lilly’s Phase 3 Breakthrough Ignites Race for the Next Cancer Stock Breakout

Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. $LLY, $NTHI, $COGT, $OLMA, $BMY, $PFE

Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study

Equity

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.

Olema Pharmaceuticals (OLMA) Expected to Announce Quarterly Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-olema-pharmaceuticals-inc-stock...

Jennison Associates LLC Takes Position in Olema Pharmaceuticals, Inc. $OLMA

Jennison Associates LLC purchased a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 963,997 shares of the company's stock, valued at approximatel...

Pictet Asset Management Holding SA Trims Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Pictet Asset Management Holding SA lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 69.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 502,568...

Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell"

Wall Street Zen raised Olema Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Monday...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen brokerages that are covering the company, Marketbeat...

Olema Pharmaceuticals (NASDAQ:OLMA) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Olema Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Sunday...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Update

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling...

Olema Pharmaceuticals (NASDAQ:OLMA) Raised to "Sell" at Wall Street Zen

Wall Street Zen upgraded shares of Olema Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday...

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Current Price	$9.87
Prev Close	$9.75
Open	$9.77
Dividend Yield	0.00%
50-Day Moving Average	$13.96
Beta	1.01
Avg. Volume	1.15M
PE Ratio	-4.87

52-Week High	$36.26
52-Week Low	$3.90
Market Capitalization	$862.12M
EPS (Annual)	-$1.87
Price to Book	1.79
Revenue Per Employee	$0.00

OLMAOlema Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OLMA News